Medications

Farxiga approved to reduce risk for CKD progression

(HealthDay)—Farxiga (dapagliflozin) oral tablets are now approved for adults with chronic kidney disease at risk for disease progression, the U.S. Food and Drug Administration announced Friday.

Pediatrics

Using big data to save babies

Although bronchopulmonary dysplasia (BPD)—a chronic lung disease affecting newborns—is the most common complication of preterm birth, it remains difficult to diagnose and treat. Researchers from Fundación INFANT in Buenos ...

Cardiology

Heart failure cases soar globally

The number of patients with heart failure worldwide nearly doubled from 33.5 million in 1990 to 64.3 million in 2017. That's the finding of a study published today in the European Journal of Preventive Cardiology, a journal ...

Cardiology

A novel drug target for neonatal and infant heart failure

Researchers have identified a new druggable target for heart failure in neonates and infants, a condition for which there has been no specific treatment. Approximately 60 percent of children born with congenital heart abnormalities ...

page 1 from 32